Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
- Author:
Jaehyun BAE
1
;
Taegyun PARK
;
Hyeyoung KIM
;
Minyoung LEE
;
Bong-Soo CHA
Author Information
- Publication Type:Review
- From:Diabetes & Metabolism Journal 2021;45(3):326-336
- CountryRepublic of Korea
- Language:English
- Abstract: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.
